Cardiac resynchronization therapy indications

Revision as of 05:47, 25 February 2022 by Sara Zand (talk | contribs) (/* 2012 ACCF/AHA/HRS Focused Update of the 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities (DO NOT EDIT){{cite journal |vauthors=Epstein AE, DiMarco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LK, Page RL, Schoenfeld MH, Silka MJ, Stevenson LW, Sweeney MO, Tracy CM, Epstein AE, Darbar D, DiMarco JP, Dunbar SB, Estes NA, Ferguson TB, Hammill SC, Karasik PE, Link MS, Marine JE, Schoenfeld MH, Sha...)
Jump to navigation Jump to search

Cardiac resynchronization therapy Microchapters

Home

Overview

Indications

Landmark Trials

Contraindications

Pathophysiologic Basis for CRT

Treatment

Preoperative Evaluation

Procedure

Recovery

Outcomes and Prognosis

Complications

Cardiac resynchronization therapy indications On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Cardiac resynchronization therapy indications

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Cardiac resynchronization therapy indications

CDC on Cardiac resynchronization therapy indications

Cardiac resynchronization therapy indications in the news

Blogs on Cardiac resynchronization therapy indications

Directions to Hospitals Administering Cardiac resynchronization therapy

Risk calculators and risk factors for Cardiac resynchronization therapy indications

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-In-Chief: Bhaskar Purushottam, M.D. [2], Hardik Patel, M.D.

Overview

Cardiac resynchronization therapy (CRT) with or without an implantable cardiac defibrillator (ICD) is indicated in patients who have an LVEF less than or equal to 35%, left bundle branch block (LBBB) with a QRS duration greater than or equal to 0.15 seconds, and normal sinus rhythm, for the treatment of NYHA functional Class III or ambulatory Class IV heart failure symptoms in patients whose medical therapy has been optimized.

Indications

References

Template:WH Template:WS CME Category::Cardiology